Aytu BioScience, Inc.(AYTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AYTU Aytu BioScience, Inc.

Post-Mkt 12-11 19:27:49 EST

2.28

+0.00

0.00%

盘后2.28

+0.000.00%

16:04 EST

High2.38	Low2.27	Vol82.77K
Open2.32	D1 Closing2.28	Amplitude4.82%
Mkt Cap23.23M	Tradable Cap12.98M	Total Shares10.19M
T/O192.28K	T/O Rate1.45%	Tradable Shares5.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AYTU","market":"US","secType":"STK","nameCN":"Aytu BioScience, Inc.","latestPrice":2.28,"timestamp":1765486800000,"preClose":2.28,"halted":0,"volume":82771,"hourTrading":{"tag":"盘后","latestPrice":2.28,"preClose":2.28,"latestTime":"16:04 EST","volume":155,"amount":353.4,"timestamp":1765487042983},"delay":0,"floatShares":5694400,"shares":10188208,"eps":-1.917869,"marketStatus":"Post-Mkt","change":0,"latestTime":"12-11 19:27:49 EST","open":2.32,"high":2.38,"low":2.27,"amount":192283.2747,"amplitude":0.048246,"askPrice":2.37,"askSize":2,"bidPrice":2.27,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.917869,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765501200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.28,"preHourTrading":{"tag":"盘前","latestPrice":2.28,"preClose":2.28,"latestTime":"09:29 EST","volume":48,"amount":109.44,"timestamp":1765463370088},"postHourTrading":{"tag":"盘后","latestPrice":2.28,"preClose":2.28,"latestTime":"16:04 EST","volume":155,"amount":353.4,"timestamp":1765487042983},"volumeRatio":1.87263,"impliedVol":2.5831,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AYTU/tweets","defaultTab":"tweets","newsList":[{"id":"2590558112","title":"Aytu Biopharma Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2590558112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590558112?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:06","pubTimestamp":1765400804,"startTime":"0","endTime":"0","summary":"Aytu Biopharma Inc. held its annual meeting of stockholders on December 10, 2025. All incumbent directors standing for reelection were elected by the stockholders. The appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ended June 30, 2026 was approved. An advisory vote regarding executive compensation was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nNDL7wNpG2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"gpt_icon":0},{"id":"2590868845","title":"Aytu BioPharma Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2590868845","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590868845?lang=en_us&edition=fundamental","pubTime":"2025-12-10 18:40","pubTimestamp":1765363200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AYTU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2025 05:40 ET (10:40 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"gpt_icon":0},{"id":"2586526490","title":"Aytu BioPharma Presents at Noble Capital Markets Emerging Growth Equity Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586526490","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586526490?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:05","pubTimestamp":1764018316,"startTime":"0","endTime":"0","summary":"Aytu BioPharma Inc. will participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, taking place at Florida Atlantic University in Boca Raton, FL. The company's management is scheduled to present on Wednesday, December 3rd at 10:30 a.m. Eastern time. A video webcast of the presentation will be available the following day on Aytu BioPharma's website, as well as on the NobleCon and Channelchek websites. Management will also conduct one-on-one meetings with investors during the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on November 24, 2025, and is solely responsible for the information contain","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL1Tpjft:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"gpt_icon":0},{"id":"2584547529","title":"Aytu Biopharma Unveils Strategic Focus on CNS Therapeutics and EXXUA Launch in Latest Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2584547529","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584547529?lang=en_us&edition=fundamental","pubTime":"2025-11-19 01:09","pubTimestamp":1763485756,"startTime":"0","endTime":"0","summary":"Aytu Biopharma Inc. has released a corporate presentation outlining its recent strategic realignment and operational developments. The company reported a $34.7 million adjusted EBITDA improvement over a four-year period, reflecting a focus on its prescription pharmaceutical business. Key recent events include the completion of the wind-down and divestiture of its consumer health segment, refinancing of its term loan, and the transition to a U.S.-based third-party contract manufacturer. In June 2025, Aytu Biopharma entered into an exclusive agreement to commercialize EXXUA in the United States. The presentation also details the company's prescription portfolio, primarily targeting central nervous system  conditions, and highlights its commercial infrastructure, which includes a direct sales force covering a significant portion of the major depressive disorder and ADHD markets. The Aytu RxConnect Patient Access Program is featured as a platform developed to enhance patient access, afford","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL2w6ykY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"gpt_icon":0},{"id":"2583026235","title":"Aytu BioScience (AYTU) Gets a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2583026235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583026235?lang=en_us&edition=fundamental","pubTime":"2025-11-14 22:35","pubTimestamp":1763130920,"startTime":"0","endTime":"0","summary":"In a report released today, Thomas Flaten from Lake Street reiterated a Buy rating on Aytu BioScience, with a price target of $8.00. According to T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aytu-bioscience-aytu-gets-a-buy-from-lake-street-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aytu-bioscience-aytu-gets-a-buy-from-lake-street-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AYTU","BK4007"],"gpt_icon":0},{"id":"2583514491","title":"Aytu BioPharma Q1 revenue beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2583514491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583514491?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:14","pubTimestamp":1763068457,"startTime":"0","endTime":"0","summary":"Aytu BioPharma Q1 revenue beats expectationsOverviewAytu fiscal Q1 2026 revenue of $13.9 mln beats analyst expectationsNet income for fiscal Q1 2026 rises to $2.0 mln from $1.5 mln year agoAdjusted EB","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP185:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"gpt_icon":0},{"id":"2583511227","title":"Aytu Biopharma Q1 Revenue USD 13.888 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511227?lang=en_us&edition=fundamental","pubTime":"2025-11-14 05:05","pubTimestamp":1763067901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLXDDAB14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AYTU"],"gpt_icon":0},{"id":"2582327400","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2582327400","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582327400?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:00","pubTimestamp":1762945200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·CI&T Inc. Class A                               3Q       .10        AMC. ·Digi Intl Inc.                                  4Q       .51    4:00 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND","CCAP","AUTL","ALC","ABOS","BEEM","CABA","ATXS","CRMD","CSCO","AMAT","ALH","ANNX","ABSI","ALMS","PYPD","BLDP","AFYA","AKRO","CURI","AVBP","TWFG","ARDT","ACXP","IMRX","BABA","LUNG","CLBT","CRMT","AEBI","AYTU","CELC","MGX","AEMD","CREX","RSKD","ARX","AFCG","GUTS","IBTA","AIRG","ALVO","CAAP","ALUR","ARCO","CINT","ABEO","CPRT","ATAT"],"gpt_icon":1},{"id":"2578952902","title":"Aytu BioPharma Secures Patent Extension for EXXUA Through 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=2578952902","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578952902?lang=en_us&edition=fundamental","pubTime":"2025-10-28 21:00","pubTimestamp":1761656458,"startTime":"0","endTime":"0","summary":"Aytu BioPharma Inc. has announced that the U.S. Patent and Trademark Office has granted a five-year extension for the method of use patent  covering EXXUA  extended-release tablets. This extension secures exclusivity for EXXUA through September 2, 2030, expanding on the new chemical entity  exclusivity previously provided by the FDA. EXXUA, the first-in-class selective serotonin 5HT1a receptor agonist for major depressive disorder  in adults, is expected to launch commercially in 2025. The company is also exploring additional intellectual property strategies that may further extend exclusivity beyond 2030. No other organizations are named as recipients of this grant or regulatory approval.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL88Zs7m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"gpt_icon":0},{"id":"2578547429","title":"Aytu Biopharma Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2578547429","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578547429?lang=en_us&edition=fundamental","pubTime":"2025-10-25 04:03","pubTimestamp":1761336230,"startTime":"0","endTime":"0","summary":"Aytu BioPharma Inc. has announced that its 2026 annual meeting of stockholders will be held in Denver, Colorado on December 10, 2025. During the meeting, stockholders will vote on the election of five directors to serve until the next annual meeting of stockholders or until their successors are duly elected and qualified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDLbVNbNL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"gpt_icon":0},{"id":"2575942217","title":"Aytu Biopharma Inc. Publishes Corporate Presentation Highlighting Focus on CNS Therapeutics and Strategic Growth Initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2575942217","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575942217?lang=en_us&edition=fundamental","pubTime":"2025-10-14 23:41","pubTimestamp":1760456460,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief on October 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL1RDkv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"gpt_icon":0},{"id":"2574179193","title":"Aytu Biopharma Inc to Participate in Planet MicroCap Showcase Toronto 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2574179193","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574179193?lang=en_us&edition=fundamental","pubTime":"2025-10-10 21:00","pubTimestamp":1760101216,"startTime":"0","endTime":"0","summary":"Aytu Biopharma Inc., a pharmaceutical company focused on innovative medicines for central nervous system diseases, will participate in the Planet MicroCap Showcase: TORONTO 2025 on October 22-23, 2025. The company's management is scheduled to present at 2:30 p.m. Eastern time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL7wNBhZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AYTU","BK4007"],"gpt_icon":0},{"id":"2570106092","title":"Aytu BioPharma Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2570106092","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570106092?lang=en_us&edition=fundamental","pubTime":"2025-09-25 20:14","pubTimestamp":1758802440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AYTU/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 25, 2025 08:14 ET (12:14 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"gpt_icon":0},{"id":"2570278017","title":"Aytu BioPharma Loses US$2.3m Market Value But Insiders See Windfall Of US$58k","url":"https://stock-news.laohu8.com/highlight/detail?id=2570278017","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570278017?lang=en_us&edition=fundamental","pubTime":"2025-09-25 19:05","pubTimestamp":1758798348,"startTime":"0","endTime":"0","summary":"Insiders who bought Aytu BioPharma, Inc. ( NASDAQ:AYTU ) stock lover the last 12 months are probably not as affected by...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aytu/aytu-biopharma/news/aytu-biopharma-loses-us23m-market-value-but-insiders-see-win","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aytu/aytu-biopharma/news/aytu-biopharma-loses-us23m-market-value-but-insiders-see-win","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","AYTU"],"gpt_icon":0},{"id":"2570927086","title":"Aytu BioPharma price target lowered to $7 from $9 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2570927086","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570927086?lang=en_us&edition=fundamental","pubTime":"2025-09-25 00:16","pubTimestamp":1758730601,"startTime":"0","endTime":"0","summary":"Maxim lowered the firm’s price target on Aytu BioPharma (AYTU) to $7 from $9 and keeps a Buy rating on the shares. Published first on TheFly – the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aytu-biopharma-price-target-lowered-to-7-from-9-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aytu-biopharma-price-target-lowered-to-7-from-9-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AYTU","BK4007"],"gpt_icon":0},{"id":"1132751842","title":"Aytu BioPharma Unveils Strategy Targeting $22 Billion Major Depressive Disorder Market","url":"https://stock-news.laohu8.com/highlight/detail?id=1132751842","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132751842?lang=en_us&edition=fundamental","pubTime":"2025-09-24 23:32","pubTimestamp":1758727934,"startTime":"0","endTime":"0","summary":"Aytu BioScience, Inc. (AYTU) has outlined its launch strategy for EXXUA, targeting the substantial $22 billion major depressive disorder market. The company is strategically pivoting its focus toward...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU","SINA"],"gpt_icon":0},{"id":"2569704114","title":"Aytu BioScience (AYTU) Receives a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2569704114","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569704114?lang=en_us&edition=fundamental","pubTime":"2025-09-24 20:45","pubTimestamp":1758717918,"startTime":"0","endTime":"0","summary":"Lake Street analyst Thomas Flaten maintained a Buy rating on Aytu BioScience today and set a price target of $8.00. The company’s shares closed yes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aytu-bioscience-aytu-receives-a-buy-from-lake-street-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aytu-bioscience-aytu-receives-a-buy-from-lake-street-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AYTU"],"gpt_icon":0},{"id":"2569481744","title":"Stocks to Watch: Aytu BioPharma, Cohu, Cyclerion","url":"https://stock-news.laohu8.com/highlight/detail?id=2569481744","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569481744?lang=en_us&edition=fundamental","pubTime":"2025-09-24 07:17","pubTimestamp":1758669420,"startTime":"0","endTime":"0","summary":"Aytu BioPharma reported quarterly revenue below Wall Street's expectations, and a wider loss than anticipated. The stock fell 14% to $2.16 after the bell on Tuesday.Cohu plans to offer $200 million in convertible senior notes due in 2031. Shares declined 10% to $20.59 in after-hours trading.Cyclerion Therapeutics entered a licensing agreement with the Massachusetts Institute of Technology securing intellectual property for its strategic relaunch. The stock soared 39% to $4.21.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0031619046.USD","LU0566484027.USD","AYTU","IE00B19Z6F94.USD","BK4007","COHU","BK4147","IE00B19Z4B17.USD","CYCN","LU1559883803.SGD","IE00B66KJ199.SGD","BK4139","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2569674515","title":"Aytu BioPharma Q4 EPS $(2.92) Misses $(0.04) Estimate, Sales $15.135M Miss $17.922M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2569674515","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569674515?lang=en_us&edition=fundamental","pubTime":"2025-09-24 04:06","pubTimestamp":1758657966,"startTime":"0","endTime":"0","summary":"Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(2.92) per share which missed the analyst consensus estimate of $(0.04) by 7791.89 percent. This is a 256.1 percent decrease over losses of $(0.82) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47829950/aytu-biopharma-q4-eps-2-92-misses-0-04-estimate-sales-15-135m-miss-17-922m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Aytu BioPharma Q4 EPS $(2.92) Misses $(0.04) Estimate, Sales $15.135M Miss $17.922M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"gpt_icon":0},{"id":"2569745922","title":"Aytu Biopharma Reports Fiscal 2025 Results: Net Revenue Rises to $66.4 Million, Net Loss at $13.6 Million, Adjusted EBITDA Reaches $9.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2569745922","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569745922?lang=en_us&edition=fundamental","pubTime":"2025-09-24 04:05","pubTimestamp":1758657929,"startTime":"0","endTime":"0","summary":"Aytu Biopharma Reports Fiscal 2025 Results: Net Revenue Rises to $66.4 Million, Net Loss at $13.6 Million, Adjusted EBITDA Reaches $9.2 Million. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aytu Biopharma Inc. published the original content used to generate this news brief via ACCESS Newswire  on September 23, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250923:nNDL2RhbRv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AYTU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aytubio.com","stockEarnings":[{"period":"1week","weight":0.0704},{"period":"1month","weight":0.0909},{"period":"3month","weight":-0.0087},{"period":"6month","weight":0.1692},{"period":"1year","weight":0.3818},{"period":"ytd","weight":0.3412}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.049556},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.165758},{"month":3,"riseRate":0.333333,"avgChangeRate":0.196783},{"month":4,"riseRate":0.5,"avgChangeRate":-0.047807},{"month":5,"riseRate":0.25,"avgChangeRate":-0.101133},{"month":6,"riseRate":0.375,"avgChangeRate":0.032109},{"month":7,"riseRate":0.375,"avgChangeRate":-0.022822},{"month":8,"riseRate":0,"avgChangeRate":-0.185643},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.05021},{"month":10,"riseRate":0.333333,"avgChangeRate":0.212856},{"month":11,"riseRate":0.111111,"avgChangeRate":-0.084654},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.071863}],"exchange":"NASDAQ","name":"Aytu BioScience, Inc.","nameEN":"Aytu BioScience, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aytu BioScience, Inc.(AYTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aytu BioScience, Inc.(AYTU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aytu BioScience, Inc.,AYTU,Aytu BioScience, Inc.股票,Aytu BioScience, Inc.股票老虎,Aytu BioScience, Inc.股票老虎国际,Aytu BioScience, Inc.行情,Aytu BioScience, Inc.股票行情,Aytu BioScience, Inc.股价,Aytu BioScience, Inc.股市,Aytu BioScience, Inc.股票价格,Aytu BioScience, Inc.股票交易,Aytu BioScience, Inc.股票购买,Aytu BioScience, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aytu BioScience, Inc.(AYTU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aytu BioScience, Inc.(AYTU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction